Loading
Paper cited by one bottleneck page and 22 idea pages, indexed on Europe PMC as PubMed record 29710129 and published in JAMA Oncology; the citing pages link this DOI, which is how the record was matched.
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 29710129 (DOI 10.1001/jamaoncol.2018.0977). Matched by DOI alone: one bottleneck page and 22 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
Shares Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211, Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Manufacturing cost and time for living and radioactive medicines.
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.